The Nexvax2 vaccine reprograms the disease-causing T-cells activated by an immune response to gluten in an approach similar to treatment for other allergies. The treatment reduces inflammation in the villi that line the small intestine.
The funding will go toward clinical trials to demonstrate proof-of-concept, and ImmusanT expects to start the next clinical trial in 2012.
Related Articles on Celiac Disease:
Specialists Urge Close Lymphoma Screening for Celiac Patients Due to High Risk
Celiac Disease Treatment Differs Between Physicians and Academics
Celiac Cases Rising, Cause Unknown
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
